MenuMenu

  1. Home
  2. Special Focus
  3. Fighting the Pandemic
  4. Indonesia’s BPOM approves first homegrown Covid-19 vaccine

Indonesia’s BPOM approves first homegrown Covid-19 vaccine

IndoVac showed an efficacy rate of 92 per cent, with "generally mild" reported side effects and no reports of deaths linked to it in trials.

2018_09_21_54405_1537525799._large.jpg

October 3, 2022

IndoVac showed an efficacy rate of 92 per cent, with “generally mild” reported side effects and no reports of deaths linked to it in trials.

scroll to top